Abbott-Solvay deal no earth-shaker

Forbes' Matthew Herper says Abbott Laboratories' (ABT) purchase of Solvay Pharmaceuticals isn't going to change the company in a big way, but the price was right. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.